/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

IMMUNIC INC

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$0.6696 -0.0031(-0.31%) IMUX at 04 Dec 2025 04:35 PM Biotechnology
Lowest Today 0.63765
Highest Today 0.6718
Today’s Open 0.665
Prev. Close 0.652
52 Week High 1.39
52 Week Low 0.56
Day’s Range: Low 0.63765 High 0.6718
52-Week Range: Low 0.56 High 1.39
1 day return -
1 Week return -8.83
1 month return -5.79
3 month return -16.1
6 month return -15.41
1 year return -48.0
3 year return -51.85
5 year return -96.4
10 year return -

Institutional Holdings

Aberdeen Group PLC 8.36

Bvf Inc 7.76

Soleus Capital Management, L.P. 7.39

Avidity Partners Management LP 5.69

abrdn Healthcare Investors 4.80

Vanguard Group Inc 4.18

Morgan Stanley - Brokerage Accounts 3.68

abrdn Life Sciences Investors 3.07

Vanguard Total Stock Mkt Idx Inv 2.61

The Colony Group LLC 2.58

LAURION CAPITAL MANAGEMENT LP 1.93

Omega Fund Management LLC 1.81

Adage Capital Partners Gp LLC 1.42

Geode Capital Management, LLC 0.99

Vanguard Institutional Extnd Mkt Idx Tr 0.97

Ikarian Capital, LLC 0.93

Ghisallo Capital Management LLC 0.85

BlackRock Inc 0.71

Fidelity Extended Market Index 0.50

abrdn World Healthcare 0.48

RTW INVESTMENTS, LLC 0.41

UBS Group AG 0.38

State Street Corp 0.34

Northern Trust Corp 0.26

BOOTHBAY FUND MANAGEMENT, LLC 0.24

Extended Equity Market Fund K 0.23

iShares Micro-Cap ETF 0.22

Fidelity Total Market Index 0.16

Renaissance Technologies Corp 0.13

Vifag 2002 SICAV 0.13

Fidelity Series Total Market Index 0.13

Bridgeway Ultra-Small Company Market 0.12

NT Ext Equity Mkt Idx Fd - NL 0.11

Spartan Extended Market Index Pool F 0.11

Northern Trust Extended Eq Market Idx 0.10

NT Ext Equity Mkt Idx Fd - L 0.10

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.09

Vanguard Instl Ttl Stck Mkt Idx Tr 0.07

Vanguard Instl Ttl Stk Mkt Idx InstlPls 0.07

Spartan Total Market Index Pool G 0.06

Market Status

Strong Buy: 5

Buy: 2

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 78.43 M

PB Ratio 8.1561

PE Ratio 0.0

Enterprise Value 47.33 M

Total Assets 40.87 M

Volume 1356365

Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-128514000 -128.5M, FY22:-154296000 -154.3M, FY21:-92794000 -92.8M, FY20:-43959000 -44.0M, FY19:-34826000 -34.8M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:-43000 -0.0M, Q1/2025:-43000 -0.0M, Q3/2024:null 0.0M, Q2/2024:-31000 -0.0M

Quarterly Net worth Q3/2025:-25579000 -25.6M, Q2/2025:-26820000 -26.8M, Q1/2025:-25473000 -25.5M, Q3/2024:-24368000 -24.4M, Q2/2024:-21380000 -21.4M

Fund house & investment objective

Company Information Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

Organisation Biotechnology

Employees 90

Industry Biotechnology

CEO Dr. Daniel Vitt Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow